[1]
|
Fracchioli, S., Puopolo, M., De La Longrais, I.A., Scozzafava, M., Bogliatto, F., Arisio, R., Micheletti, L. and Katsaros, D. (2006) Primary “Breast-Like” Cancer of the Vulva: A Case Report and Critical Review of the Literature. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 423-428.
|
[2]
|
Grossl, N. (2000) Supernumerary Breast Tissue: Historical Perspectives and Clinical Features. Southern Medical Journal, 93, 29-32. https://doi.org/10.1097/00007611-200001000-00004
|
[3]
|
Simon, K.E., Dutcher, J.P., Runowicz, C.D. and Wiernik, P.H. (1988) Adenocarcinoma Arising in Vulvar Breast Tissue. Cancer, 62, 2234-2238.
https://doi.org/10.1002/1097-0142(19881115)62:10<2234::AID-CNCR2820621027>3.0.CO;2-F
|
[4]
|
Lopes, A., Louis, J.St., Balancin, M.L., Barbosa, E.M., Costa, R.L.R., et al. (2018) A Rare Presentation of Primary Breast Carcinoma in the Vulva: A Case Report and Literature Review. Clinical Breast Cancer, 18, e291-e294.
https://doi.org/10.1016/j.clbc.2017.06.004
|
[5]
|
Yang, Z., Li, N., Li, X., Lei, L. and Wang, X. (2020) The Prognostic Impact of Hormonal Receptor and HER-2 Expression Discordance in Metastatic Breast Cancer Patients. OncoTargets and Therapy, 13, 853-863.
https://doi.org/10.2147/OTT.S231493
|
[6]
|
Vinay, D.S. and Kwon, B.S. (2018) Harnessing Immune Checkpoints for Cancer Therapy. Immunotherapy, 10, 1265-1284.
https://doi.org/10.2217/imt-2017-0168
|
[7]
|
Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science (New York, NY), 359, 1350-1355. https://doi.org/10.1126/science.aar4060
|
[8]
|
Wei, P.C., Duffy, C.R. and Allison, J.P. (2018) Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. Cancer Discovery, 8, 1069-1086. https://doi.org/10.1158/2159-8290.CD-18-0367
|
[9]
|
Marra, A., Viale, G. and Curigliano, G. (2019) Recent Advances in Triple Negative Breast Cancer: The Immunotherapy Era. BMC Medicine, 17, 90. https://doi.org/10.1186/s12916-019-1326-5
|
[10]
|
Schmid, P., Rugo, H.S., Adams, S., Schneeweiss, A., et al. (2018) Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. The New England Journal of Medicine, 379, 2108-2121.
|
[11]
|
Schmid, P., Rugo, H.S., Adams, S., Schneeweiss, A., et al. (2020) Atezolizumab Plus Nab-Paclitaxel as First-Line Treatment for Unresectable, Locally Advanced or Metastatic Triple-Negative Breast Cancer (IMpassion130): Updated Efficacy Results from a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 44-59.
|
[12]
|
Intra, M., Maggioni, A., Sonzogni, A., DE Cicco, C., Machado, L.S., Sagona, A. and Talakhadze, N. (2006) A Rare Association of Synchronous Intraductal Carcinoma of the Breast and Invasive Carcinoma of Ectopic Breast Tissue of the Vulva: Case Report and Literature Review. International Journal of Gynecological Cancer: Official Journal of the International Gynecological Cancer Society, 428-433.
|